Truist assumes Genmab stock coverage with buy rating on pipeline By Investing.com

Truist initiated coverage on Genmab A/S with a Buy rating and a $40 price target, implying upside from the current $26.89 share price despite cutting its target from $48. The firm highlighted Genmab’s transition to a more commercially driven platform, with up to seven key readouts expected in 2026 and pipeline assets such as Epkinly, Rina-S, and petosemtamab as catalysts. Genmab also reported Q1 2026 revenue growth of 25% year over year, supported by EPKINLY, TIVDAK, and royalty streams.

Analysis

GMAB is increasingly a de-risked “pipeline + royalty” story rather than a single-asset biotech, which matters because the market typically underwrites that mix at a lower multiple than pure commercial peers until it sees repeated execution. The key second-order effect is that each positive readout in 2026 can incrementally re-rate not just the lead programs but the durability of the royalty stream, since investors will begin treating royalty cash flows as a funding engine for external BD rather than a legacy drag. That usually compresses the perceived funding gap and lowers the equity risk premium by 100-200 bps if management avoids dilution.

The bigger setup is timing asymmetry: the stock can rerate months before definitive sales inflection if the next few clinical readouts validate label expansion or best-in-class positioning. In biotech, a multi-catalyst year tends to create a “trial stack” effect where each derisking event increases the implied probability of the next one, so the market often moves more on sequence than on absolute magnitude. If the 2026 catalysts land well, the hidden winner is the company’s ability to finance follow-on assets on better terms; if they disappoint, the downside is amplified because expectations are already shifting toward commercial self-sufficiency.

Consensus appears to be underappreciating the option value embedded in the platform transition. The market is still likely valuing GMAB as a mid-teens growth royalty name, but successful execution on multiple shots on goal can justify a materially higher multiple if the company demonstrates that proprietary medicines can offset future royalty normalization. The main contrarian risk is that investors may be paying up for a story that looks clean on paper but remains binary on readout quality, not just revenue growth.

The near-term tape is likely range-bound until catalysts become more proximate, which creates a window for structured exposure rather than outright chasing strength. For risk assets in biotech, the best opportunities often come when the market is focused on the next quarter’s earnings optics while the real re-rating driver sits 6-12 months out.

Key Decisions for Investors

• Initiate a starter long in GMAB now and add on pre-data weakness into the next 6-9 month catalyst window; target a 15-25% upside re-rating if early readouts validate the platform transition, with downside limited to the low-20s if execution remains intact.
• For event-driven exposure, buy GMAB Jan-2027 calls or call spreads to capture the 2026 readout stack; prefer spreads to reduce theta while preserving upside if multiple catalysts land positively.
• Pair trade: long GMAB / short a slower-growing royalty-heavy biotech at a richer multiple to isolate execution and catalyst dispersion; the thesis is GMAB’s mix shift should outperform if the market starts rewarding commercial capability over passive royalty income.
• If the stock rallies sharply ahead of data, sell upside calls against core long exposure to finance carry; biotech reratings often overshoot into catalysts, and implied volatility should remain attractive for overwrite strategies.